Earnings Call
Apr 28, 2026
Q1 FY2026
EPS Estimate
1.32
EPS Actual
1.81
Post-Earnings Close
$97.74
Earnings Reaction
+2.1%
Incyte opened 2026 with broad-based commercial momentum, posting total revenues of $1.27 billion and net product sales of $1.10 billion, both up roughly 20-21% year-over-year. Every marketed product grew, both domestically and internationally, and the company reaffirmed full-year net sales guidance of $4.77 billion to $4.94 billion, a 10-13% increase over 2025. The headline beat was driven not just by Jakafi, which grew a solid 7% to $758 million on 6% prescription demand growth, but increasingly by the ex-Jakafi portfolio, which surged 63% year-over-year to roughly $340 million. That diversification story is central to the investment thesis: management is deliberately engineering a transition away from Jakafi dependence toward a multi-franchise hematology, oncology, and immunology business they believe can generate $3-4 billion in ex-Jakafi revenue by 2030.
Report generated on Apr 28, 2026
AI-generated earnings analysis. Not investment advice.
Chief Executive Officer
The quarter's results reflected a combination of company-specific execution and broader sector dynamics, with management addressing several of the key debates that analysts had flagged heading into the print. Guidance commentary pointed to continued momentum in the core segments, while questions on margins and capital allocation drew more nuanced responses from the leadership team over the course of the call.
The quarter's results reflected a combination of company-specific execution and broader sector dynamics, with management addressing several of the key debates that analysts had flagged heading into the print. Guidance commentary pointed to continued momentum in the core segments, while questions on margins and capital allocation drew more nuanced responses from the leadership team over the course of the call.
The quarter's results reflected a combination of company-specific execution and broader sector dynamics, with management addressing several of the key debates that analysts had flagged heading into the print. Guidance commentary pointed to continued momentum in the core segments, while questions on margins and capital allocation drew more nuanced responses from the leadership team over the course of the call.
Read the full INCY analysis
The complete report, with key themes, analyst Q&A summary, notable quotes, and market context — is free with an account. No password, no card.